ANIP
ANI Pharmaceuticals, Inc.·Healthcare
82.72
0.060%(−0.05)
Market ClosedLast Updated: — ET
52W L: $57.3352W H: $99.50
ANIP NEWS
zacks.com
May 15
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
zacks.com
May 15
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
zacks.com
May 15
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
zacks.com
May 13
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
fool.com
May 11
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.
zacks.com
May 11
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
